FIGURE 1.

Percent of patients in the terlipressin treatment group who had HRS reversal^a by baseline serum creatinine subgroup (terlipressin group, pooled ITT population^b). ^aThe incidence of HRS reversal across the 3 Phase III studies was defined as at least 1 serum creatinine value of ≤1.5 mg/dL while on treatment (on treatment was defined as up to 24 h after the final dose of study drug) by Day 14 or discharge. ^†Pooled data were collated from the following Phase III studies: OT-0401, REVERSE, and CONFIRM. Abbreviations: HRS indicates hepatorenal syndrome; ITT, intent-to-treat.